INTRODUCTION

With up to 20% of surgical resections for suspected biliary malignancy showing benign final pathology, pancreatobiliary stricture malignancy detection is an area where progress needs to be made. Even with careful clinicopathologic correlation, pancreatobiliary stricture specimens remain a common source of false negatives in general and false positives in primary sclerosing cholangitis (PSC). UroVysion (U-FISH), which was developed for urothelial cancer, is the most commonly used ancillary method for biliary strictures but remains underutilized despite repeated reports that it increases sensitivity. It is a fluorescent in situ hybridization (FISH) assay that uses four probes; 3 pericentromeric probes for chromosomes 3, 7, and 17 as well as a probe for the 9p21 band. Aneuploidy is a near-universal event in solid tumors and >66% show whole chromosome alterations. The chromosomes

Abstract

Pancreatobiliary strictures are a common source of false negatives for malignancy detection. UroVysion is more sensitive than any other method but remains underutilized because of conflicting sensitivities and specificities due to a lack of standardized cutoff criteria and confusion in interpreting results in the context of primary sclerosing cholangitis. We set out to determine the sensitivities and specificities of UroVysion, brushing cytology, forceps biopsies, and fine needle aspiration (FNAs) for pancreatobiliary stricture malignancy detection. A retrospective review was performed of all biopsied pancreatobiliary strictures at our institution over 5 years. UroVysion was unquestionably the most sensitive method and all methods were highly specific. Sensitivity was highest while maintaining specificity when a malignant interpretation was limited to cases with 5+ cells with the same polysomic signal pattern and/or loss of one or both 9p21 signals. Only UroVysion detected the metastases and a neuroendocrine tumor. In reviewing and analyzing the signal patterns, we noticed trends according to location and diagnosis. Herein we describe our method for analyzing signal patterns and propose cutoff criteria based upon observations gleaned from such analysis.

KEYWORDS
cytogenetics, cytopathology, FISH, pancreatobiliary, stricture
targeted by U-FISH contain some of the most commonly implicated solid tumor driver genes and in terms of whole chromosomes aneusomies gain of 7 is the most common gain in solid tumors.31 Aneuploidy in malignancies results from caretaker gene alterations that cause DNA repair defects which eventually manifest as chromosomal instability (CSI).32 Even though CSI is not an initiating event, it is implicated in cancer progression and the process is nonrandom.33 Patterns of aneuploidy are now being associated with different tumors so in addition to being sensitive, detecting aneuploidy can be specific enough in a given case to support one diagnosis over another.32

1.1 Genetics of malignancies in pancreatobiliary strictures

A summary of the reported cytogenetic abnormalities detectable by U-FISH for each of the commonly encountered diagnoses in pancreatobiliary strictures can be found in Table 1. For comparison, the most common driver mutations are included along with their corresponding chromosomes. While at least one of the whole chromosome aneusomies involving chromosomes 3, 7, and 17 or 9p21 have been reported in each diagnosis, these findings are more common and significant in some of the diagnoses than others. For most of these tumors, these aneusomies are often late events seen due to CSI, but for gallbladder adenocarcinoma and pancreatic neuroendocrine tumors (pNETs) these are more common and significant, respectively. Carcinomas originating in the gallbladder or cystic duct are genetically heterogeneous and while mutations in many genes have been reported, whole chromosome aneusomies detected by U-FISH probes are more common than mutations in any of the twenty most associated genes.34 In pNETs neoplasia is driven more by aneuploidy than single-gene mutations.35 Lawrence et al. describe two patterns of aneuploidy that correlate with distinct histologic features and clinical outcomes.35 Two-thirds of sporadic pNETs show one of these two patterns which result in the biallelic inactivation of MEN1 after the loss of heterozygosity in chromosome 11.35 Chromosome 3 is the only chromosome represented by U-FISH that is aneusomic in one of the two patterns.

1.2 Biliary U-FISH

Since the first report on the use of U-FISH in pancreatobiliary strictures, U-FISH has repeatedly been shown to be more sensitive than cytology with reported sensitivities from 31% to 84% and specificities from 83% to 100%.12,13,24 FISH is less specific in patients with PSC and in such cases, serial measurements are important to prevent false positives.29,36,37 The main weakness of U-FISH for pancreatobiliary strictures is the lack of standardized and optimized criteria; this explains the large range of sensitivities and specificities and provides a promising area for improvement in maximizing preoperative malignancy detection.

The most common polysomotic threshold is five cells with more than two copies of at least two of the probes, excluding tetrasomy. Some people use four cells as is done in urine.17 While the 9p21 probe was initially disregarded, it has become apparent over time that 9p21 can be indicative of malignancy even in the absence of polysomy. This is the main area of confusion as criteria for 9p21 loss have varied tremendously. Proposed criteria have included: loss of one or both signals in five cells, loss of one signal in 10 cells, loss of two signals

| Tumor | Reported cytogenetic abnormalities (with frequencies where available) detectable by UroVysion | Most common molecular findings (chromosome on which gene sits in parentheses) |
|-------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Intrahepatic cholangiocarcinoma | Del 9p21 | IDH1 (2), IDH2 (15), KRAS (12), BRAF (7), TP53 (17), ARID1A (1), BAP1 (3), PBRM1 (3) mutations; FGFR2 (10) translocations |
| Extrahepatic cholangiocarcinomas | +3(7%), +7(29%), −3(7%), −7(14%), −9(36%), −17 (36%) | KRAS (12), CDKN2A (9), TP53 (17), SMAD4 (18) mutations; ERBB2 (17) amplification |
| Pancreatic ductal adenocarcinoma | +3(22%), +7(19%), +9(11%), +17(6%), −3(17%), −7(3%), −9(25%), −17 (56%) | KRAS (12), TP53 (17), CDKN2A (9), SMAD4 (18), BRCA1 (17), BRCA2 (13) mutations |
| Gallbladder adenocarcinoma | +3(10%), +7(50%), +17(30%), −3(10%), −7(20%), −9(60%), −17 (50%) | TP53 (17), KRAS (12), CDKN2A (9) mutations |
| Ampullary carcinomas | −7, −9, −17 | KRAS (12), TP53 (17), APC (3) mutations |
| Acinar carcinoma | 3 infrequently lost or gained, +7 > −7, −9 > +9, +17 > −17 | APC promoter (3) methylation>loss>>mutation |
| pNET | −3 | Biallelic MEN1 (11) inactivation |

Abbreviation: pNET, pancreatic neuroendocrine tumor.
in 10 cells, loss of one or both signals in 12 cells, loss of both signals in 5%, loss of one signal in 6%, and loss of signals in 20% cells.5,12,13,17,18,21 While trisomy 7 was once considered sufficient for malignancy detection by some it has become evident that its presence is essentially noncontributory in malignancy detection.4,16,21 It is usually grouped with trisomy 3 and its presence is simply noted or an equivocal interpretation is rendered when either is seen in 10 cells or 10% of cells.21,29 Tetrasomy has been deemed a nonspecific finding and either grouped with trisomy or its presence specifically noted when seen in 10 cells or 10% of cells.21,29 In PSC, polysomy can be seen in the absence of malignancy and reverts over half the time, so serial or multifocal positivity and clinical evidence of malignancy are necessary.9,11,20 In PSC, positive FISH findings can be seen in dysplasia.38 Polysomy can be seen over a year before pathologic or radiologic evidence of malignancy.11 For these reasons, it is recommended that FISH be repeated when polysomy is detected in the absence of other evidence of malignancy and close monitoring of repeat polysomic results is recommended despite the length of time elapsed since the initial polysomy result.11 Although established as the most clinically relevant ancillary technique, with professional associations such as the Papanicolaou Society of Cytopathology even recommending its routine usage, U-FISH is rarely used for pancreaticobiliary strictures.2 This is likely at least in part due to initial reports of low specificity resulting from trisomy 7 criteria being applied as independently sufficient for malignancy detection as well as from a lack of understanding as to how to interpret results in the context of PSC. Rare experiments with different FISH probes have been no more sensitive than U-FISH when both polysomy and 9p21 criteria are used.21 While one might surmise that advances in next-generation sequencing (NGS) would surely allow for a clinically useful panel of sufficient size to supersede U-FISH, Dudley et al. reported their NGS panel containing nearly every driver gene from Table 1 to be only comparable to U-FISH when both polysomy and 9p21 criteria were not used.25 As an in situ technique, and in contrast to NGS, FISH allows visual confirmation that the mutation is present in and limited to the morphologically atypical cells. In comparison to NGS, FISH is far more sensitive, requiring fewer atypical cells and a lower tumor fraction.21 While resections are performed for cases that are benign but thought to be malignant, this is usually the result of resection based solely upon radiologic findings when a biopsy cannot be obtained or when biopsies have been repeatedly negative despite concerning clinical and radiologic findings. The main issue is insensitivity. Pancreatobiliary strictures and malignancies are notorious for yielding paucicellular lesional samples because of the effects of fibrosis and desmoplasia. For this reason, and because of the particularly low tumor fraction with the often abundant non-lesional gastrointestinal epithelial contamination that inevitably results because of the difficulty in sampling these lesions, FISH may provide unique promise in this area.

In this paper, we report on the 5-year experience of a large academic medical center in using cytology, forceps biopsies, and U-FISH to diagnose pancreaticobiliary strictures. We provide insights from signal pattern analysis and criteria recommendations that in our experience have increased sensitivity while preserving specificity.

2 | MATERIALS AND METHODS

2.1 | Patient population

At the approval of the institutional review board, the cytogenetics database was queried to identify all pancreaticobiliary brushing U-FISH specimens at our institution from October 2014 to November 2019. From this list, a patient list was generated and no patients or specimens were excluded.

2.2 | Specimen collection

All strictures were biopsied with some combinations of brushing ± forceps biopsy and/or FNA. For each case, one brushing was placed in CytoLyt (Hologic Inc.) for the creation of a ThinPrep (Hologic Inc.) and another was placed in saline for UroVysion (Abbott Molecular Inc.). Forceps biopsies were collected in formalin. FNAs were collected in CytoLyt for the creation of ThinPreps.

2.3 | FISH interpretation

A cytogenetic technologist screened the slides and recorded signal patterns on a score sheet before a cytogeneticist reviewed the cases and produced final reports. Specimens were considered positive if criteria were met for polysomy or 9p21 loss. Polysomy was defined as three or more signals for two or more probes in five or more cells unless there were exactly four signals for each probe. Loss of 9p21 was defined as loss of one or two 9p21 signals in five or more cells. Specimens were considered equivocal if they had 10 or more cells with tetrasomy or trisomy. All other specimens were considered negative.

2.4 | Signal pattern analysis

Score sheets were reviewed to ensure the proper interpretation of signal patterns and to generate an inferred cytogenetic sequence for each case. The cytogenetic sequence responsible for the observed signal patterns in a case was inferred from the consideration of the reported relative frequencies of each aneusomy detectable by U-FISH for a particular diagnosis as well
as how these would most likely result in the observed signals. See Table 1 for reported frequencies of U-FISH-detectable aneusomies and Figures 1–4 for a stepwise approach and examples that clarify the signal pattern analysis process.

### 2.5 | Morphologic interpretation

Pancreatobiliary cytology specimens that showed atypical cells of quantitative or qualitative insufficiency for a malignant interpretation were diagnosed as atypical with a qualifier understood by our clinicians to indicate the pathologist’s level of concern. The qualifiers in order of increasing suspicion include “cannot exclude malignancy,” “suspicious for malignancy,” “favor malignancy,” and “consistent with malignancy.”

### 2.6 | Other data collection

The medical record for each patient was comprehensively reviewed. To call a case benign there had to be a lack of evidence of malignancy on follow-up imaging at least 12 months after the brushing collection as well as a known benign candidate etiology and complete stricture resolution without the resolution being due to resection, chemotherapy, or radiation. To call a case malignant there had to be histologic evidence or both compelling radiologic evidence of metastasis and the absence of another candidate lesion for the site of origin.

### 3 | RESULTS

The study included 181 encounters and 154 patients. There were 126 encounters in 113 patients whose strictures were ultimately determined to be of benign etiology. There were 55 encounters in 41 patients whose strictures were ultimately determined to be of malignant etiology. In total, there were 52 encounters in 39 patients with PSC. Other than the one false positive, PSC cases did not show different FISH signal patterns from other benign and malignant cases. Of these, 43 of the encounters occurred in the 34 patients whose strictures were ultimately determined to be of benign etiology. Overall, there were 20 people with multiple encounters resulting in 27 repeat encounters. Repeat encounters for malignant lesions (n = 11) were excluded from analysis for calculating sensitivities of individual methods. Of the 55 malignant lesions, 14 had only negative encounters. If an encounter with multiple specimen types consists entirely of negative results for a lesion that is known to be malignant, it is more likely that the multiple concurrent specimens are all negative as a result of failing to sample the lesion than as a result of the insensitivity of the techniques. Sensitivities calculated by excluding such negative encounters can highlight and reduce the effect of sampling. This may more accurately represent the sensitivity of the technique and allow for a more meaningful comparison between results from specimens obtained by different endoscopists and from different lesions.

Brushing cytology and U-FISH were attempted in all cases, but in 12 cases (nine benign, three malignant) the brush for U-FISH contained insufficient cells and in three cases (two benign, one malignant) the cytology brush resulted in an acellular liquid-based preparation. It was more common for the FISH brush to contain insufficient cells but it was always collected after the cytology brush. This and there being no cases in which both were insufficient indicate that such cases are more likely the result of the collection than insensitivity of the analytical method. For this reason, insufficient results were excluded from statistical analysis instead of being considered as true or false negatives.

| Cell # | CEP17 | LSI 9p21 | CEP3 | CEP 7 |
|--------|-------|---------|------|-------|
| 1      | 4     | 2       | 4    | 4     |
| 2      | 4     | 2       | 4    | 4     |
| 3      | 4     | 2       | 4    | 4     |
| 4      | 4     | 2       | 4    | 4     |
| 5      | 4     | 2       | 4    | 4     |

**FIGURE 1** This is an abridged representation of an actual score sheet from one of the pancreatic ductal adenocarcinoma (PDAC) cases. The signal patterns could mistakenly be attributed to independent gains of 3, 7, and 17. This pattern is instead the result of hemizygous loss of 9p21 followed by whole-genome doubling. As shown in Table 1, in PDACs loss of 9 is more common than the gain of 3, 7, or 17.
Table 2 shows the sensitivities and specificities of each method at different cutoffs. FISH was by far the most sensitive method. All methods were of high specificity. The one false-positive FISH was in a case of PSC and showed an increase in all probe signals in seven cells, increases in all probe signals with no 9p21 signals in three cells, increased signals for all but the 9p21 probe in eight cells, increased CEP3 and CEP7 signals in four cells, increased CEP7 and CEP 17 signals with no 9p21 signals in one cell, an increase in CEP7 and only one 9p21 signal in one cell,
and an increase in the CEP7 signal in one cell. There were ten cases in which only U-FISH was positive. This included four pancreatic ductal adenocarcinomas (PDACs), two distal cholangiocarcinomas (DCs), one intrahepatic cholangiocarcinoma (IHC), both metastases and one of the three pNETs. Only brushing cytology was positive for one IHC and one PDAC. There were no cases where only forceps biopsy or FNA was positive.

Table 3 contains the diagnoses, FISH interpretations, abnormal signal patterns, and inferred cytogenetic sequences for each malignant case. From the ERCP reports, the precise location of the stricture was determined and cholangiocarcinomas were divided into intrahepatic, proximal extrahepatic, and distal extrahepatic types. If the stricture was centered proximal to the common hepatic duct origin, it was classified as IHC. If the stricture was centered in the common hepatic duct it was classified as extrahepatic proximal cholangiocarcinoma. If the stricture was centered distal to the cystic duct origin it was classified as DC.

4 | DISCUSSION

4.1 | The importance of signal pattern analysis

The pancreatobiliary U-FISH literature describes polysomy as if it usually results from multiple independent gains when in actuality most polysomic cells in the context of pancreatobiliary malignancy are the result of whole-genome doubling (WGD). Unlike benign cells, which are only tetrasomic after DNA replication during the S phase and until cytokinesis, malignant cells are often tetraploid or near-tetraploid outside this window due to aberrations in DNA replication or cell division. Tetraploidy can result in multipolar spindle formation and cytogenetic instability. The role of WGD in bringing about polysomy has not been emphasized and polysomy has been touted as the single most important U-FISH finding, while tetrasomy has been assessed as nonspecific and something that must be distinguished from polysomy so as to preserve the specificity of polysomy. Polysomy is, indeed, more specific for malignancy than tetrasomy, but it is important to recognize tetrasomy, WGD, and the role they play in generating polysomy. Analysis of signal patterns with tetrasomy and WGD in mind elucidates the sequence of cytogenetic changes that resulted in the detected polysomy. Figure 3 illustrates the potential consequences of simply looking for polysomic cells without considering the cytogenetic mechanisms responsible for the polysomic cells.

In most cases, a review of the U-FISH signal patterns from a polysomic case reveals that the polysomic cells arose out of tetraploid cells or otherwise abnormal cells that underwent WGD. Examples and further explanations of this can be found in Figures 1, 2, and 4. Of the 37 malignant cases detected by U-FISH, sequential gains preceded WGD.
in only five cases (see Inferred Genetic Sequence column of Table 3). Moreover, 9p21 loss preceded WGD in 62% (23/37) of cases. This explains why optimization of 9p21 criteria is key to improving sensitivity, especially sensitivity for earlier stage cases that are more likely to be amenable to resection and in which FNA may be contraindicated.

4.2 | Proposed criteria based on signal pattern analysis

4.2.1 | Same polysomic signal pattern in five cells = positive for malignancy

Our data support a criterion requiring five polysomic cells that show the same signal pattern. Fewer cells may be too nonspecific as we had two negative cases with three polysomic cells. See Figure 3 for an example that illustrates the importance of requiring the same signal pattern. Requiring five cells of the same type seems reasonably restrictive as all of our positive malignant cases and none of our benign cases except the one false-positive case met this criterion. Trying to adapt the criteria to exclude the false-positive case would result in unacceptably low sensitivity and would be unnecessary since the false positive was in a person with PSC in whom one should know not to overvalue a single positive polysomic result.

4.2.2 | Loss of one or two 9p21 signals in even five cells = positive for malignancy

Our data support the 9p21 criterion for malignancy proposed by Kubiliun et al. of five cells with either a homozygous or hemizygous loss. While there are occasional benign cases that show the rare cell with 9p21 signal loss, the most we saw in a benign case was three cells except for our one known false positive. We had one IHC and one PDAC each with only six cells showing homozygous 9p21 signal loss as well as a pNET with hemizygous 9p21 signal loss in only five cells, so requiring more than five cells would likely result in a significantly reduced sensitivity. Others have proposed 5% but when few cells are present this could result in overcalling malignancy.

4.2.3 | Tetrasomy in 10% = equivocal

While tetrasomic cells are encountered in benign specimens, they are usually few in number. Barr Fritcher et al. report that 40% of cases showing 10 or more tetrasomic cells are malignant. The most we saw in a benign case was seven tetrasomic cells in a case where 73 cells were counted. For this reason, we propose that any cell containing 10% tetrasomic cells be noted.

| Interpreted as positive | Sensitivity (%) | Specificity (%) |
|-------------------------|----------------|----------------|
| Brushing cytology (n = 178) |                |                |
| Adenocarcinoma only     | 24             | 100            |
| Suspicious, favor, consistent with, and adenocarcinoma | 46 | 100 |
| Suspicious, favor, consistent with, and adenocarcinoma excluding negative encounters | 63 | 100 |
| Forceps biopsy (n = 68) |                |                |
| Adenocarcinoma only     | 24             | 100            |
| Suspicious, favor, consistent with, and adenocarcinoma | 36 | 100 |
| Suspicious, favor, consistent with, and adenocarcinoma excluding negative encounters | 47 | 100 |
| FNA (n = 39)            |                |                |
| Adenocarcinoma only     | 32             | 100            |
| Suspicious, favor, consistent with, and adenocarcinoma | 39 | 100 |
| Suspicious, favor, consistent with, and adenocarcinoma excluding negative encounters | 60 | 100 |
| Brushing FISH (n = 169) |                |                |
| Polysomy                | 58             | 99             |
| Polysomy or loss of 9p21 | 71              | 99             |
| Polysomy or loss of 9p21 excluding negative encounters | 95 | 99 |

| Interpretations considered positive | Sensitivity (%) | Specificity (%) |
|-------------------------------------|----------------|----------------|
| Criteria for positive interpretation |                |                |
| Polysomy                            | 58             | 99             |
| Polysomy or loss of 9p21             | 71             | 99             |
| Polysomy or loss of 9p21 excluding negative encounters | 95 | 99 |

*Negative encounters consist of encounters with multiple specimens all with negative results for a lesion that is independently confirmed to have been malignant. See the main text for an explanation as to why this is a meaningful value to report.
| Eventual diagnosis | FISH interpretation | Abnormal cell signal patterns | Inferred cytogenetic sequence |
|--------------------|---------------------|-------------------------------|------------------------------|
| IHC<sup>a</sup>    | Positive            | • P3/7/17<sup>b</sup> L9(2)<sup>f</sup> (12 cells) • P3/7/17 L9(1) (2 cells) | • L9(1) then WGD<sup>d</sup> |
|                    | Positive            | • P3/7/9/17 (6 cells) • TR9<sup>f</sup> (2 cells) | • TR9 then WGD |
|                    | Positive            | • P3/7/9/17 (7 cells) • TR7 (10 cells) | • G17<sup>g</sup> then G7 |
|                    | Positive            | • TR7 L9(2) (25 cells) | • TR7 |
|                    | Positive            | • TR7 L9(1) (25 cells) | • TR7 and L9(2) (OCBD)<sup<h</sup> |
|                    | Positive            | • TR3 L9(2) (28 cells) • TR3 (8 cells) | • TR3 then L9(2) |
|                    | Positive            | • L9(1) (10 cells/10% of total) | • L9(1) |
|                    | Positive            | • L9(2) (6 cells) | • L9(2) |
|                    | Negative            | • P3/7 (1 cell) • TR3 (1 cell) | N/A<sup>i</sup> |
|                    | Negative            | • P3/7/17 L9(2) (1 cell) • TE (1 cell) | N/A |
| IHC (PSC)<sup>j</sup> | Positive            | • TR3 (1 cell) | TR3 then L9(2) |
|                    | Negative            | Insufficient cells for U-FISH<sup>k</sup> | N/A |
| EHPC<sup>l</sup>    | Positive            | • P3/7/17 L9(2) (25 cells) | TR7 and L9(2) (OCBD) then WGD |
|                    | Positive            | • P3/7/9/17 (5 cells) • P3/7/9 (1 cell) • P3/9/17 (2 cells) • P3/7/17 (8 cells) | TR7 |
|                    | Positive            | • P3/7/9/17 (17 cells) • P3/7/17 (8 cells) | G3 then G17 then WGD |
|                    | Negative            | • P3/7/9/17 (7 cells) • P3/7/9 (3 cells) • P7/9/17 (6 cells) • TR7 (1 cell) • P3/7/17 (25 cells) | N/A |
| EHPC (PSC)          | Positive            | • P3/7/17 L9(2) (1 cell) • P3/7/9/17 (21 cells) • P3/7 (3 cells) | L9(1) then WGD |
|                    | Positive            | • P3/7/17 (25 cells) | L9(2) then WGD |
| DC<sup>m</sup> (involving proximal CBD and distal CHD) | Positive            | • P3/7/9/17 (14 cells) • P7/9/17 (1 cell) • TR7 (19 cells) • TR3 (1 cell) | WGD then RLAG • TR7 |
|                    | Negative            | • P3/7/9 (1 cell) | TR7 |
| DC (involving proximal CBD and distal CHD) (PSC) | Positive            | • P3/7/9/17 (12 cells) • TR7 (23 cells) | TR7 then G3 |
|                    | Negative            | Insufficient cells for U-FISH | N/A |
| IPNB (proximal CBD) | Positive            | • L9(1) L17(1) (109 cells) • P3/7 (17 cells) • P3/7/9 (1 cell) | L9(1) then L17(1) then WGD |
|                    |                     | • G3 (3 cells) | TR7 then G9 |

(Continues)
| Eventual diagnosis                      | FISH interpretation | Abnormal cell signal patterns | Inferred cytogenetic sequence                                      |
|-----------------------------------------|---------------------|-------------------------------|---------------------------------------------------------------------|
| **DC (middle CBD)**                     | Positive            | •P3/7/9 (1 cell)              | •P3/7/17 (18 cells) •P3/7 (6 cells) •L9(1) then WGD then L17(1) G7 |
| Positive                                | •P3/7/17 (22 cells) | •P3/7 (1 cell)                | •P3/17 (1 cell) •L9(1) then WGD                                      |
| Negative                                | NASP                |                               | WGD then RLAG                                                        |
| **DC (distal CBD)**                     | Positive            | •P3/7/9/17 (11 cells)         | L9(2) then G17 then G7 •L9(2) then G17 then WGD                     |
| Negative                                | NASP                |                               |                                                                     |
| **Mixed acinar-ductal pancreatic cancer**| Positive            | •P3/7/17 L9(2) (2 cells)      | •P7/17 L9(2) (10 cells) •TR17 L9(2) (15 cells) •L9(2) then G17 then G7 |
| Positive                                | •P3/7/17 L9(2) (12 cells) | •TR7 (11 cells)       | •L9(2) then WGD •TR7                                               |
| Positive                                | •G7 L9(2) (6 cells)  | •P3/7/9 (6 cells)             | •P3/7 (1 cell) •TR7 then L9(2) •TR7 then G9 then G3                |
| Positive                                | •P3/7/9/17 (25 cells) | •P7/9/o (4 cells)         | •L9(2) then WGD •L9(2) then G17 then G7                            |
| Positive                                | •P3/7/17 (9 cells)   | •P7/9/17 (1 cell)            | •TE (1 cell) •WGD                                                  |
| Positive                                | •P3/7/17 (2 cells)   | •P7/17 (1 cell)              | •L9(1) then WGD •L9(2) then WGD                                    |
| Positive                                | •P3/7/17 (5 cells)   | •P7/17/17 (2 cells)          | •TE (4 cells) •L9(1) then WGD                                      |
| Positive                                | •P3/7/17 (9 cells)   |                               |                                                                     |
| Positive                                | •P3/7/17 (12 cells)  | •TE (2 cells)                | •L9(1) then WGD •L9(2) then WGD                                    |
| Positive                                | •P3/7/17 L9(2) (8 cells) | •TR7 (1 cell)            | •L9(1) then WGD •L9(2) then WGD                                    |
| Positive                                | •P3/7/17 L9(2) (2 cells) | •TR3 (2 cells)            | •L9(1) then WGD •L9(2) then WGD                                    |
| Positive                                | •P3/7/17 (16 cells)  | •P3/7/17 (1 cell)            | •L9(1) then WGD •L9(2) then WGD                                    |
| Positive                                | •P3/7/9 (3 cells)    | •P7/9 (1 cell)               | •L9(1) then WGD •L9(2) then WGD                                    |
| Positive                                | •L9(2) (75 cells)    | •TR7 (1 cell)                | •L9(2) then WGD •L9(2) then WGD                                    |
| Positive                                | •TR3 L9(2) (1 cell)  | •G3 (1 cell)                 | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | •P3/7/9/17 (1 cell)  | •P3/7/17 (1 cell)            | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | •TR7 (10 cells)      | •TR7 L17 (2 cells)           | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | •TR7 (8 cells)       |                               | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | •P3/7 (2 cells)      |                               | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | •TE (1 cell)         |                               | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | •L17 (1) (13 cells)  |                               | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | NASP                |                               | •L9(2) then WGD •L9(2) then WGD                                    |
| Negative                                | NASP                |                               | •L9(2) then WGD •L9(2) then WGD                                    |
| **Ampullary carcinoma**                 | Positive            | •P7/9/17 (13 cells)          | •G7 (2 cells) •G7 then G9 G17 (OCBD)                               |
| **Gallbladder adenocarcinoma**          | Positive            | •P7/9/17 L9(2) (25 cells)    | •L9(2) then WGD •P3/7/9/17 (3 cells) •P3/9/17 (1 cell) •G3 then G17 then WGD |
| Positive                                | •P3/17 (21 cells)    | •P3/7/9/17 (3 cells)         | •L9(2) then G17 then WGD •G3 then G17 then WGD                     |
| Negative                                | •L9(1) G17 (1 cell)  | •TE (1 cell)                 | N/A                                                                 |

(Continues)
4.2.4 | Trisomy 7 alone = negative

Although it is now generally accepted that cases with trisomy 7 are more likely to be benign than malignant, there have been people who considered the presence of trisomy 7 as sufficient for malignancy detection.4,12,14,16 As with other criteria, different thresholds have been proposed to achieve higher specificity. In our cohort, there were benign cases in patients with and without PSC that each had trisomy 7 in more than 25 cells and more than 30% of the cells. We had benign cases where trisomy 7 was no longer apparent a month later and others where it persisted for more than 3 years, so even persistence is not diagnostic of malignancy.

For these reasons, we do not think there is any threshold at which trisomy 7 alone should be considered positive for malignancy detection. We recommend against an equivocal interpretation because of the frequency with which trisomy 7 is seen and the devaluation of an equivocal interpretation if used so commonly and in so many cases that end up benign.

4.2.5 | Trisomy 3 in 10+ cells = equivocal

Since U-FISH has been used on pancreateobiliary strictures trisomy 3 has been regarded similarly to trisomy 7 with many reports even lumping the two together without specifying which is present. But while trisomy 7 is seen very frequently in benign pancreateobiliary strictures, trisomy 3 is rarely seen in benign pancreateobiliary strictures.

Only seven cases of pancreateobiliary strictures with trisomy 3 have been reported and only one was malignant.4,12,15,24 Only Kubiliun et al. reported the number of cells with trisomy 3 for each of their cases.12 It was...
specified that 2 of their benign cases had fewer than 10 cells with trisomy 3, while a third case had 12 cells with trisomy 3. The malignant case, reported by Chaiteerakij et al., was a PDAC in which the cells with trisomy 3 were also homozygous for loss of the 9p21 locus.

Our data significantly add to what has been reported and show trisomy 3 to be both common in malignant cases as well as more common in malignant than benign cases. Trisomy 3 cells were seen in one benign case, one negative specimen targeting a subsequently confirmed malignancy, and five malignant specimens. Two DCs and one PDAC each showed a single cell with trisomy 3. All three cases contained tetraploid populations and the complex variety of signal patterns typical of such cases, so in these cases, the trisomy is likely of little significance and represents a random event. In one IHC 19 cells showed trisomy 3, 18 of which also showed homozygous 9p21 loss. In another IHC 36 cells showed trisomy 3, 28 of which also showed homozygous 9p21 loss.

While we have recommended refraining from an equivocal interpretation for trisomy 7, our data support attention to trisomy 3, especially when seen in an intrahepatic lesion and even more so when seen in greater than 10 cells. The one reported benign case that had more than 10 cells with trisomy 3 was a PDAC. Other than the cases reported by Kubiliun et al., all previously reported benign cases with trisomy 3 were from studies that did not consider 9p21 probe status in assessing for malignancy detection. Malignancy was only detected preoperatively by 9p21 criteria. Our data show that not only is hemizygous 9p21 loss seen at a frequency similar to that of homozygous loss in pancreatobiliary malignancy, but that this is underappreciated without the consideration of WGD and that there may be a location-dependent pattern to 9p21 loss. In our cohort, homozygous and hemizygous 9p21 losses were seen with near equal frequencies in IHCs, peripancreatic EHCs, and PDACs. However, all three DCs with 9p21 loss showed hemizygous loss.

### 4.3 Other insights from signal pattern analysis

Discrepancies between previously reported sensitivities and specificities may be explained by our finding that signal patterns vary by location and diagnosis. WGD occurs later in IHC than in extrahepatic cholangiocarcinoma (EHC) or PDAC. At the time of the first positive U-FISH result, WGD was seen in 33% of IHC (3/9), 100% of EHC (12/12), and 78% of PDAC (7/9). Because WGD occurs late in IHC, polysomy criteria are often not positive at the time of brushing. Polysomy criteria were not met in 67% (6/9) of detected IHCs and said cases were only detected by 9p21 criteria.

Hemizygous 9p21 signal loss is far less reported than homozygous loss and it has even been suggested that hemizygous loss is specific to low-grade dysplasia. Our data show that not only is hemizygous 9p21 loss seen at a frequency similar to that of homozygous loss in pancreatobiliary malignancy, but that this is underappreciated without the consideration of WGD and that there may be a location-dependent pattern to 9p21 loss. In our cohort, homozygous and hemizygous 9p21 losses were seen with near equal frequencies in IHCs, peripancreatic EHCs, and PDACs. However, all three DCs with 9p21 loss showed hemizygous loss.

### 4.3.2 Normal or decreased number of CEP3 signals in extrahepatic lesion may indicate a less common diagnosis

While most malignant pancreatobiliary strictures are the result of PDAC or cholangiocarcinoma, several other diagnoses can present as pancreatobiliary strictures. We had several noteworthy cases that are all relatively rare in pancreatobiliary strictures and otherwise unique in that they are the only positive cases in our cohort outside the liver that showed a normal number of CEP3 signals. They included an ampullary carcinoma with intestinal differentiation, a mixed ductal-acinar pancreatic carcinoma (confirmed via outside expert consultation), an intraductal papillary neoplasm of the bile duct (IPNB), and a pNET. This could be useful in alerting one to consider a less common diagnosis which is particularly helpful in this area of oncology where immunohistochemistry is ineffective in determining tissue of origin and malignant cases are usually diagnosed as adenocarcinoma with clinicians expected to determine the specific diagnosis based on the clinical presentation. While clinical correlation is
reasonable for differentiating PDACs and cholangiocarcinomas, it is insufficient for distinguishing the less common entities which are often misdiagnosed until resection.

To summarize, polyploidy in pancreatobiliary malignancy most often results from WGD as opposed to multiple independent gains. In the majority of cases, 9p21 loss precedes WGD, but WGD in the absence of 9p21 loss and WGD in the absence of sequential independent gains are each responsible for polyploidy in nearly one-fifth of such cases. Signal patterns vary by location and diagnosis. The CEP3 signal appears to be affected in all primary tumors encountered in pancreatobiliary strictures except IHC, intestinal ampullary carcinoma, pancreatic acinar carcinoma, and the in-situ component of IPNB. Awareness of these principles is important because it informs how one interprets the sequence of cytogenetic events and this sequence may provide diagnostic information that is not apparent without signal analysis.

In conclusion, we provide new criteria that could increase the sensitivity while maintaining the specificity of U-FISH for malignancy detection in pancreatobiliary strictures. Our report is particularly contributory for its level of detail on stricture location, FISH signal pattern, and signal pattern analysis. Subsequent studies on specific signal patterns and the changes responsible for them may allow for even more refined criteria that could improve upon the already superior sensitivity and near-perfect specificity of U-FISH in this area where current methods are unable to accurately detect malignancy preoperatively in a remarkably high proportion of cases.

5 | ANALYZING SIGNAL PATTERNS

Step 1. Identify the cell(s) with the greatest number of signals for a single probe.

Step 2. Determine the most probable sequence of events that could result in a cell with this signal pattern.

- If there is no cell with at least four signals for one or more probes, then the number of gains and losses is usually few and can be explained simply by the relative expected frequency of each aneusomy for each probe for the tumor type.
- If the number of signals for any of the probes is four or more in any of the cells, one should first determine if it is most likely that such cells arose from tetrasomic cells, aneusomic cells that underwent WGD, or from a series of gains and losses in diploid cells. This requires and is facilitated by consideration of the other observed signal patterns.

Step 3. Repeat steps 1 and 2 until all observed signal patterns have been accounted for.

ETHICAL APPROVAL STATEMENT
This project was approved by the Institutional Review Board of the Human Research Protection Program at the University of Kansas Medical Center. It conforms with the US Federal Policy for the Protection of Human Subjects.

ACKNOWLEDGMENTS
We have no one to acknowledge as everyone involved is an author and no funding was required for this project.

CONFLICT OF INTEREST
None of the authors have any conflicts of interest to report.

AUTHOR CONTRIBUTION
Daniel Mettman, Shivani Golem, Mojtaba Olyaee, and Maura O'Neil contributed to the conception, design, data acquisition, data analysis, manuscript drafting, and manuscript revision; Azhar Saeed, Janna Shold, Raquele Laury, Andrew Ly, and Irfan Khan contributed to data acquisition, data analysis, manuscript drafting, and manuscript revision.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Daniel Mettman https://orcid.org/0000-0003-1735-8925

REFERENCES
1. Martinez NS, Trindade AJ, Sejpal DV. Determining the indeterminate biliary stricture: cholangioscopy and beyond. Curr Gastroenterol Rep. 2020;22(12):58.
2. Adler DG, Witt B. Cytologic diagnosis of biliary strictures: fish or cut the sensitivity rate? Dig Dis Sci. 2018;63(3):549-550.
3. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99(9):1675-1681.
4. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131(4):1064-1072.
5. Levy MJ, Clain JE, Clayton A, et al. Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc. 2007;66(3):483-490.
6. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology
for detecting cholangiocarcinoma in primary sclerosing cholangitis. *Hepatology.* 2008;48(4):1106-1117.
7. Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. *Am J Gastroenterol.* 2008;103(5):1263-1273.
8. Barr Fritcher EG, Kipp BR, Halling KC, et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreaticobiliary strictures. *Gastroenterology.* 2009;136(7):2180-2186.
9. Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. *Hepatology.* 2010;51(1):174-180.
10. Kipp BR, Barr Fritcher EG, Clayton AC, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreaticobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. *J Mol Diagn.* 2010;12(6):780-786.
11. Fritcher EBG, Kipp BR, Voss JS, et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. *Am J Gastroenterol.* 2011;106(11):2023-2028.
12. Kubiliun N, Ribeiro A, Fan Y-S, et al. EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. *Gastrointest Endosc.* 2011;74(3):541-547.
13. Gonda TA, Glick MP, Sethi A, et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. *Gastrointest Endosc.* 2012;75(1):74-79.
14. Smoczyński M, Jablonska A, Matyskiel A, et al. Routine brush cytology and fluorescence in situ hybridization for assessment of pancreaticobiliary strictures. *Gastrointest Endosc.* 2012;75(1):65-73.
15. Barr Fritcher EG, Voss JS, Jenkins SM, et al. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19–9 predict risk of malignancy. *Cancer Cytopathol.* 2013;121(12):708-717.
16. Henkes DN, Patel SN, Rosenkranz LA, Escobedo JL. The utility of U-FISH fluorescence in situ hybridization in pancreatic fine-needle aspiration samples directed and obtained by endoscopic ultrasonography. *Arch Pathol Lab Med.* 2013;137(1):64-71.
17. Vlajnic T, Somaini G, Savic S, et al. Targeted multiprobe fluorescence in situ hybridization analysis for elucidation of inconclusive pancreaticobiliary cytology. *Cancer Cytopathol.* 2014;122(8):627-634.
18. Boldorini R, Paganotti A, Andorno S, et al. A multistep cytological approach for patients with jaundice and biliary strictures of indeterminate origin. *J Clin Pathol.* 2015;68(4):283-287.
19. Barr Fritcher EG, Kipp BR, Halling KC, Clayton AC. FISHing for pancreaticobiliary tract malignancy in endoscopic brushings enhances the sensitivity of routine cytology. *Cytologyopathology.* 2014;25(5):288-301.
20. Eaton JE, Fritcher EGB, Gores GJ, et al. Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. *Am J Gastroenterol.* 2015;110(2):299-309.
21. Barr Fritcher EG, Voss JS, Blankley SM, et al. An optimized set of fluorescence in situ hybridization probes for detection of pancreaticobiliary tract cancer in cytology brush samples. *Gastroenterology.* 2015;149(7):1813-1824.e1.
alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. *Hum Pathol.* 2007;38(3):491-499.

39. Krasinskas AM. Cholangiocarcinoma. *Surg Pathol Clin.* 2018;11(2):403-429.

40. Rijken AM, Hu J, Perlman EJ, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. *Genes Chromosomes Cancer.* 1999;26(3):185-191.

41. Kowalski J, Morsberger LA, Blackford A, et al. Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. *Cancer Genet Cytogenet.* 2007;178(1):26-35.

42. Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. *Cancers.* 2017;9(12):42.

43. Gorunova L, Parada LA, Limon J, et al. Nonrandom chromosomal aberrations and cytogenetic heterogeneity in gallbladder carcinomas. *Genes Chromosomes Cancer.* 1999;26(4):312-321.

44. Bernasconi B, Dossena B, Billo PR, Tibiletti MG, Sessa F. Involvement of 1p36 region in two cases of adenocarcinoma of the ampulla of Vater. *Cancer Genet Cytogenet.* 2002;138(2):133-138.

45. Pea A, Riva G, Bernasconi R, et al. Ampulla of Vater carcinoma: molecular landscape and clinical implications. *World J Gastrointest Oncol.* 2018;10(11):370-380.

46. Bergmann F, Aulmann S, Sipos B, et al. Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. *Virchows Arch.* 2014;465(6):661-672.

47. Furlan D, Sahnane N, Bernasconi B, et al. APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. *Virchows Arch.* 2014;464(5):553-564.

How to cite this article: Mettman D, Saeed A, Shold J, et al. Refined pancreatobiliary UroVysion criteria and an approach for further optimization. *Cancer Med.* 2021;10:5725–5738. [https://doi.org/10.1002/cam4.4043](https://doi.org/10.1002/cam4.4043)